Movement Alert｜Recursion Pharmaceuticals, Inc. Pre-Market Rise 5.07%, REC-4881 Phase 2 Data and Registrational Trial Plan Draw Focus

Market Focus11-11 21:05

On November 11, Recursion Pharmaceuticals, Inc. rose 5.07% in Pre-Market Trading, trading at $3.73 per share, with turnover of $1.5814 million.

The clearest catalyst was the company’s newly disclosed Phase 2 update for REC-4881, which showed a meaningful reduction in polyp burden in patients with familial adenomatous polyposis, alongside a relatively clean safety profile that supports a planned registrational trial.

Additional context around the move includes the recent appointment of pharma veteran Fred Hassan as chair of the board and third-quarter revenue of $18.55 million with a net loss of $119.04 million. Recent investor outreach also remains active, with the company scheduled to attend multiple healthcare investor conferences later in November and early December, keeping attention on whether its AI-enabled drug discovery platform can convert clinical progress into broader valuation support.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment